Intellia Therapeutics (NTLA) Other Operating Expenses (2024 - 2026)

Intellia Therapeutics (NTLA) has 3 years of Other Operating Expenses data on file, last reported at $904000.0 in Q1 2026.

• Quarterly Other Operating Expenses fell 57.46% year-over-year to $904000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (up 94.19% YoY) and the FY2025 annual result came in at -$899000.0, up 97.24% from the prior year.
• Other Operating Expenses slipped to $904000.0 in Q1 2026 per NTLA's latest filing, from $1.8 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $20.4 million in Q2 2024 and bottomed at -$62.0 million in Q4 2024.
• The 3-year median for Other Operating Expenses is $1.8 million (2025), against an average of -$3.6 million.
• Peak annual rise in Other Operating Expenses reached 102.83% in 2025, while the deepest fall reached 212.24% in 2025.
• Tracing NTLA's Other Operating Expenses over 3 years: stood at -$62.0 million in 2024, then jumped by 102.83% to $1.8 million in 2025, then slumped by 48.46% to $904000.0 in 2026.
• Per Business Quant, the three latest NTLA Other Operating Expenses figures stand at $904000.0 (Q1 2026), $1.8 million (Q4 2025), and -$3.4 million (Q3 2025).

Peer Comparison